Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
14 pending office actions • 12 art units • 14 examiners • 0 of 14 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days
Monash University is currently managing 14 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 12 distinct art units, indicating a broad technical footprint within this sector. The prosecution workload is handled by 14 distinct examiners, meaning every pending action is assigned to a different individual. This ratio of examiners to actions suggests a lack of examiner-level concentration in the current portfolio.
The busiest examiner, VU, VU A, is responsible for 1 busiest examiner pending action. Because there are many distinct examiners for the pending office actions, no single examiner holds a larger share of the workload than any other. The 12 distinct art units show that the university's patent applications are being reviewed by a wide variety of specialized groups. This ratio of 12 distinct art units to the total pending actions suggests a diverse and decentralized prosecution landscape for the university's current biotechnology and pharmaceutical filings. Practitioners must prepare for unique examiner perspectives across these 12 distinct art units.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (14%) |
| §112 only | 2 (14%) |
| Double-patenting only | 1 (7%) |
| Double-patenting + other | 1 (7%) |
| Multi-statute (no §101) | 8 (57%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VU, VU A | 1 | 92.4% | +6.6% |
| DAUNER, JOSEPH G | 1 | 56.9% | +35.2% |
| WERTZ, ASHLEE ELIZABETH | 1 | 52.9% | +42.1% |
| AZPURU, CARLOS A | 1 | 83.8% | +10.7% |
| XIE, XIAOZHEN | 1 | 56.6% | +65.8% |
| BYRD, BRIGID K | 1 | 71.4% | +46.4% |
| BUNNER, BRIDGET E | 1 | 64.5% | +19.9% |
| MIANO, JOSEPH PAUL | 1 | 36.0% | +63.3% |
| FETTEROLF, BRANDON J | 1 | 52.0% | +17.4% |
| HUDSON, AMY ROSE | 1 | 74.9% | +11.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18707515 | NEGATIVE CAPACITANCE TOPOLOGICAL QUANTUM FIELD-EFFECT TRANSISTOR | VU, VU A | — |
| 18409546 | LIPID PRODRUGS OF NEUROSTEROIDS | AZPURU, CARLOS A | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17772107 | TREATMENT OF RENAL CYSTIC DISEASE | HUDSON, AMY ROSE | 5d |
| 17771982 | ANTIBODIES FOR BINDING PLASMINOGEN | TAYLOR, LIA ELAN | 15d |
| 18291808 | LIPID NANOPARTICLE FORMULATIONS | WERTZ, ASHLEE ELIZABETH | — |
| 18273156 | FUSION PROTEINS | XIE, XIAOZHEN | — |
| 17996754 | METHODS AND COMPOSITIONS | MIANO, JOSEPH PAUL | — |
| 17792042 | COMPOSITIONS AND METHODS | FETTEROLF, BRANDON J | — |
| 17626168 | METHODS FOR MAKING RECOMBINANT PROTEIN | REGLAS, GEORGIANA C | — |
| 17598380 | A MICROPARTICLE AND/OR NANOPARTICLE SEPARATION, FILTRATION AND/OR ENRICHING DEVICE AND METHOD | BULLOCK, IN SUK C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18314951 | SURGICAL SYSTEM AND METHOD OF USE | BYRD, BRIGID K | 42d overdue |
| 17772107 | TREATMENT OF RENAL CYSTIC DISEASE | HUDSON, AMY ROSE | 5d |
| 18698074 | METHOD OF DETERMINING A TARGET POLYMER IN A SAMPLE BY USING A GUIDE POLYMER | DAUNER, JOSEPH G | — |
| 18291808 | LIPID NANOPARTICLE FORMULATIONS | WERTZ, ASHLEE ELIZABETH | — |
| 18409546 | LIPID PRODRUGS OF NEUROSTEROIDS | AZPURU, CARLOS A | — |
| 18273156 | FUSION PROTEINS | XIE, XIAOZHEN | — |
| 18001480 | IL-1 RECEPTOR ANTAGONIST (IL-1 RA) FUSION PROTEINS BINDING TO THE EXTRACELLULAR MATRIX | BUNNER, BRIDGET E | — |
| 17996754 | METHODS AND COMPOSITIONS | MIANO, JOSEPH PAUL | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| 1617 | 1 |
| 1674 | 1 |
| 3771 | 1 |
| 1647 | 1 |
| 1631 | 1 |
| 1626 | 1 |
| 1636 | 1 |
| 1641 | 1 |
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18707515 | NEGATIVE CAPACITANCE TOPOLOGICAL QUANTUM FIELD-EFFECT TRANSISTOR | VU, VU A | — | §103 | Non-Final OA | — | Pending | May 03, 2024 |
| 18698074 | METHOD OF DETERMINING A TARGET POLYMER IN A SAMPLE BY USING A GUIDE POLYMER | DAUNER, JOSEPH G | — | §102§112DP | Non-Final OA | — | Pending | Apr 03, 2024 |
| 18291808 | LIPID NANOPARTICLE FORMULATIONS | WERTZ, ASHLEE ELIZABETH | 1612 | §102§103§112 | Non-Final OA | — | Pending | Jan 24, 2024 |
| 18409546 | LIPID PRODRUGS OF NEUROSTEROIDS | AZPURU, CARLOS A | 1617 | DP | Non-Final OA | — | Pending | Jan 10, 2024 |
| 18273156 | FUSION PROTEINS | XIE, XIAOZHEN | 1674 | §102§103§112 | Non-Final OA | — | Pending | Jul 19, 2023 |
| 18314951 | SURGICAL SYSTEM AND METHOD OF USE | BYRD, BRIGID K | 3771 | §103 | Non-Final OA | 42d overdue | Pending | May 10, 2023 |
| 18001480 | IL-1 RECEPTOR ANTAGONIST (IL-1 RA) FUSION PROTEINS BINDING TO THE EXTRACELLULAR MATRIX | BUNNER, BRIDGET E | 1647 | §112 | Non-Final OA | — | Pending | Dec 12, 2022 |
| 17996754 | METHODS AND COMPOSITIONS | MIANO, JOSEPH PAUL | 1631 | §103§112 | Final Rejection | — | Pending | Oct 20, 2022 |
| 17792042 | COMPOSITIONS AND METHODS | FETTEROLF, BRANDON J | 1626 | §102§103 | Non-Final OA | — | Pending | Jul 11, 2022 |
| 17772107 | TREATMENT OF RENAL CYSTIC DISEASE | HUDSON, AMY ROSE | 1636 | §103§112 | Non-Final OA | 5d | Pending | Apr 26, 2022 |
| 17771982 | ANTIBODIES FOR BINDING PLASMINOGEN | TAYLOR, LIA ELAN | 1641 | §102§103 | Final Rejection | 15d | Pending | Apr 26, 2022 |
| 17626168 | METHODS FOR MAKING RECOMBINANT PROTEIN | REGLAS, GEORGIANA C | 1651 | §103§112 | Final Rejection | — | Pending | Jan 11, 2022 |
| 17598380 | A MICROPARTICLE AND/OR NANOPARTICLE SEPARATION, FILTRATION AND/OR ENRICHING DEVICE AND METHOD | BULLOCK, IN SUK C | 1772 | §102§103 | Non-Final OA | — | Pending | Sep 27, 2021 |
| 17328966 | METHOD OF TREATMENT | KELLY, ROBERT M | 1638 | §112 | Final Rejection | 23d overdue | Pending | May 24, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial